Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Trimeric gp140 Protein in Healthy Adults
NCT02304185Phase 1Completed
- Sponsor
- Crucell
- Start
- Dec 2014
- Primary completion
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trimeric gp140 protein in human immunodeficiency virus infection (HIV) (6 arms), sponsored by Crucell. Primary endpoints: Number of Participants With Local and Systemic Reactogenicity Events Over 8 Days After First Vaccination, Number of Participants With Local and Systemic Reactogenicity Events Over 8 Days After Second Vaccination at Day 36 and 1 more. Started Dec 2014; status: completed.
02
Drugs
trimeric gp140 protein
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02304185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304185.